AIMD Stock Overview A healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Ainos Historical stock prices Current Share Price US$0.68 52 Week High US$3.10 52 Week Low US$0.40 Beta 1.42 1 Month Change 28.50% 3 Month Change 54.55% 1 Year Change -33.98% 3 Year Change -98.35% 5 Year Change -96.98% Change since IPO -99.99%
Recent News & Updates
Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study Nov 12
Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies Oct 08
Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial Sep 26
Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona Sep 25
Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients Sep 18 See more updates
Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study Nov 12
Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies Oct 08
Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial Sep 26
Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona Sep 25
Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients Sep 18
Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety Aug 20
Ainos, Inc., Annual General Meeting, Sep 27, 2024 Aug 16
Second quarter 2024 earnings released: US$0.49 loss per share (vs US$0.58 loss in 2Q 2023) Aug 06
Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug Jul 24
Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2) Jul 20
Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA Jun 15
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market May 16
First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023) May 15
New major risk - Shareholder dilution May 08
We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt Mar 10
Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022) Mar 10
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms Feb 05
New minor risk - Shareholder dilution Jan 30
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement Jan 02
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell Dec 26
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary Dec 23
Less than half of directors are independent Dec 16
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA Nov 22
Ainos, Inc., Annual General Meeting, Dec 08, 2023 Oct 29
Ainos, Inc., Annual General Meeting, Dec 08, 2023 Oct 28
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt Aug 28
Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022) Aug 13
Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement Jul 07
Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target Jun 15
Ainos, Inc. Announces Chief Financial Officer Changes May 18
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt May 15
First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022) May 14
Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021) Apr 08
Ainos Receives Non-Compliance Notice From Nasdaq Jan 11
Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals Nov 22
Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021) Nov 16
Less than half of directors are independent Nov 16
Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and Commercialization Nov 01
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - Omicron Oct 01
Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19 Sep 30
Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19 Aug 24
Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021) Aug 16
Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M Aug 15 Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million. Aug 10
Less than half of directors are independent Aug 09
Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19 Jun 28
Ainos, Inc. Announces Executive Changes Jun 17
Ainos, Inc. announced delayed 10-Q filing Aug 18 Shareholder Returns AIMD US Biotechs US Market 7D -14.9% 1.8% -0.8% 1Y -34.0% -2.1% 22.7%
See full shareholder returns
Return vs Industry: AIMD underperformed the US Biotechs industry which returned -2.1% over the past year.
Return vs Market: AIMD underperformed the US Market which returned 22.7% over the past year.
Price Volatility Is AIMD's price volatile compared to industry and market? AIMD volatility AIMD Average Weekly Movement 23.0% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: AIMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AIMD's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products.
Show more Ainos, Inc. Fundamentals Summary How do Ainos's earnings and revenue compare to its market cap? AIMD fundamental statistics Market cap US$9.58m Earnings (TTM ) -US$16.13m Revenue (TTM ) US$40.63k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AIMD income statement (TTM ) Revenue US$40.63k Cost of Revenue US$183.98k Gross Profit -US$143.35k Other Expenses US$15.99m Earnings -US$16.13m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.15 Gross Margin -352.79% Net Profit Margin -39,705.78% Debt/Equity Ratio 68.1%
How did AIMD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 11:17 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ainos, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
